Last reviewed · How we verify
NCT04142372: HemaTMA
Tissue Microarray of Hematological Malignancies
trial in Hematological Malignancies in 5,000 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2026
Quick facts
| Lead sponsor | Tampere University Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 10 March 2020 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Finland |
Conditions studied
- Hematological Malignancies — all drugs for Hematological Malignancies →
Sponsor
Tampere University Hospital
Who can join
Eligibility, any sex, with Hematological Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04142372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematological Malignancies
Currently open trials in the same condition.
- NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
- NCT06584955 — Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies · NA · active not recruiting
- NCT06387082 — A Clinical Study of HMPL-506 in Patients With Hematological Malignancies · Phase 1 · recruiting
- NCT06150469 — Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies · NA · recruiting
- NCT06179511 — Study of AZD9829 in CD123+ Hematological Malignancies · Phase 1, PHASE2 · active not recruiting
Other Tampere University Hospital trials
Trials by the same sponsor.
- NCT07315568 — Couples and Microbial Diversity · not yet recruiting
- NCT07128992 — Need-driven Treatment of the Patients With Type 1 Diabetes · not yet recruiting
- NCT07042139 — No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older · NA · recruiting
- NCT07528833 — Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain · NA · recruiting
- NCT06711796 — Measurement of Muscle Relaxation of the Hand in From Two Muscles and Two Hand Positions · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04142372 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tampere University Hospital
- Last refreshed: 24 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04142372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing